RANDOMIZED PHASE III TRIAL OF CARBOPLATIN (AUC 7.5) AND PACLITAXEL

卡铂 (AUC 7.5) 和紫杉​​醇的随机 III 期试验

• 批准号: 6279608
• 负责人: JONATHAN S BEREK
• 金额: $ 1.77万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6279608
• 关键词: carboplatin; clinical research; combination cancer therapy; female; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; ovary neoplasms; paclitaxel; women's health

Ovarian carcinoma is the fourth most frequent cancer in women in the United States. It is newly diagnosed in 24,000 women each year, of whom 13,600 will eventually die of their disease. It is now the most common fatal gynecological malignancy, and over the past three decades, there has been a steady slow rise in ovarian cancer incidence. Unfortuanetely, only about 30 percent of ovarian carcinoma are localized and amenable to complete surgical resection at the time of their initial presentation.

卵巢癌是世界上第四大常见的女性癌症 美国。每年有2.4万名妇女新诊断为该病，其中 13,600人最终将死于他们的疾病。它现在是最常见的 致命的妇科恶性肿瘤，在过去的三十年里， 卵巢癌的发病率一直在稳步缓慢上升。 不幸的是，只有大约30%的卵巢癌是局部性的 并可在初次手术时完成手术切除 演示文稿。